Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.

Paes B, Mitchell I, Yi H, Li A, Lanctôt KL; CARESS Investigators.

Pediatr Infect Dis J. 2014 Feb;33(2):e29-33. doi: 10.1097/INF.0000000000000019.

PMID:
23989104
[PubMed - in process]
2.

Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.

Yi H, Lanctôt KL, Bont L, Bloemers BL, Weijerman M, Broers C, Li A, Kiss A, Mitchell I, Paes B; CARESS investigators.

Pediatrics. 2014 Jun;133(6):1031-7. doi: 10.1542/peds.2013-3916. Epub 2014 May 5.

PMID:
24799541
[PubMed - indexed for MEDLINE]
3.

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2703-11. Epub 2012 May 1.

PMID:
22546928
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Romero JR.

Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54.

PMID:
12671452
[PubMed - indexed for MEDLINE]
5.

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.

J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.

PMID:
20044843
[PubMed - indexed for MEDLINE]
Free Article
6.

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.

J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. Review.

PMID:
20131495
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

CARESS: the Canadian registry of palivizumab.

Mitchell I, Paes BA, Li A, Lanctôt KL; CARESS investigators.

Pediatr Infect Dis J. 2011 Aug;30(8):651-5. doi: 10.1097/INF.0b013e31821146f7.

PMID:
21343842
[PubMed - indexed for MEDLINE]
10.

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.

Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators.

Pediatr Infect Dis J. 2002 Jun;21(6):512-8.

PMID:
12182374
[PubMed - indexed for MEDLINE]
11.

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.

Paes B, Mitchell I, Li A, Lanctôt KL.

Eur J Pediatr. 2012 May;171(5):833-41. doi: 10.1007/s00431-011-1654-8. Epub 2011 Dec 28. Erratum in: Eur J Pediatr. 2012 Sep;171(9):1419.

PMID:
22203430
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.

Diehl JL, Daw JR, Coley KC, Rayburg R.

J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31.

PMID:
20044844
[PubMed - indexed for MEDLINE]
Free Article
13.

Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J; Palivizumab Outcomes Registry Group.

Pediatr Infect Dis J. 2008 Oct;27(10):870-3. doi: 10.1097/INF.0b013e318174e0c4.

PMID:
18776822
[PubMed - indexed for MEDLINE]
14.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
[PubMed - indexed for MEDLINE]
15.

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Cochrane Database Syst Rev. 2013 Apr 30;4:CD006602. doi: 10.1002/14651858.CD006602.pub4. Review.

PMID:
23633336
[PubMed - indexed for MEDLINE]
16.

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.

Paes B, Steele S, Janes M, Pinelli J.

Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112.

PMID:
19469698
[PubMed - indexed for MEDLINE]
17.

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.

Pediatr Pulmonol. 2008 Feb;43(2):169-74.

PMID:
18085710
[PubMed - indexed for MEDLINE]
18.

Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.

Paes B, Mitchell I, Li A, Harimoto T, Lanctôt KL.

Clin Dev Immunol. 2013;2013:917068. doi: 10.1155/2013/917068. Epub 2013 Jun 19.

PMID:
23861694
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.

Fryzek JP, Martone WJ, Groothuis JR.

Adv Ther. 2011 Mar;28(3):195-201. doi: 10.1007/s12325-010-0106-6. Epub 2011 Feb 7. Erratum in: Adv Ther. 2011 Dec;28(12):1126.

PMID:
21327753
[PubMed - indexed for MEDLINE]
20.

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.

Hampp C, Kauf TL, Saidi AS, Winterstein AG.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7.

PMID:
21300647
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk